US Patent

US11324734 — Compositions and methods for treating anemia

Formulation · Assigned to Akebia Therapeutics Inc · Expires 2036-03-31 · 10y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects specific doses and dosing regimens for using a HIF prolyl hydroxylase inhibitor, such as vadadustat, to treat or prevent anemia.

USPTO Abstract

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Drugs covered by this patent

Patent Metadata

Patent number
US11324734
Jurisdiction
US
Classification
Formulation
Expires
2036-03-31
Drug substance claim
No
Drug product claim
Yes
Assignee
Akebia Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.